Nitroimidazole adduct (hypoxic cell marker)

Nitroimidazole adducts are not a specific protein or receptor but rather covalent modifications of cellular macromolecules (primarily proteins) formed when 2-nitroimidazole compounds are reduced and trapped within hypoxic cells. These adducts serve as chemical markers for hypoxic tissue, allowing the detection and imaging of local hypoxia, particularly in tumors and ischemic tissues. The underlying mechanism relies on bioreductive activation under low-oxygen conditions, causing selective adduct formation and enabling their identification ex vivo (by antibody staining) or in vivo (by radiolabeled imaging agents such as FMISO or EF5)[1][2][3][4][5]. Nitroimidazole adducts themselves are not direct therapeutic targets or classical receptors, enzymes, or transporters, but their formation enables non-invasive assessment and mapping of tissue hypoxia, critical in oncology and research on ischemic diseases.

Other names

Nitroimidazole hypoxia marker2-Nitroimidazole adductNitroimidazole-based hypoxia markerHypoxia marker via nitroimidazole adduct

Under low oxygen (hypoxic) conditions, nitroimidazole compounds undergo bioreductive activation by cellular nitroreductases, leading to formation of reactive intermediates. These intermediates covalently bind to cellular macromolecules (mainly proteins), forming adducts that are retained selectively within hypoxic cells[1][2][3]. The adducts can then be detected using labeled antibodies or radiotracers for imaging or immunohistochemical methods[4][5].